Neuroone Medical Technologies Corp
NeuroOne Medical Technologies Corp (NMTC) is a small‑cap medical‑device company developing neuromodulation technologies aimed at treating neurological conditions such as chronic pain and movement disorders. With a market capitalisation around $41 million, the company is still at an early commercial and clinical stage, so investors should expect a focus on product development, regulatory milestones and clinical data rather than steady revenue. Key considerations include regulatory approvals, the strength of clinical evidence, reimbursement pathways and the potential for dilution if additional capital is required. Neuromodulation is a growing area with meaningful clinical need, but outcomes can be binary and timelines uncertain. This summary is educational and not personal advice — research the company’s filings, recent clinical updates and cash runway, and consider how a high‑volatility, speculative medical‑device stock fits within a diversified portfolio.
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Neuroone's stock with a target price of $2.23, indicating significant potential growth.
Financial Health
Neuroone Medical Technologies Corp shows moderate revenue and cash flow with healthy profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NMTC
Brain-Computer Interface
This collection features pioneering companies creating revolutionary pathways between the human brain and machines. These carefully selected stocks represent the cutting edge of neural technology, with potential to transform healthcare and computing through innovative brain signal interpretation.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Neuromodulation focus
The company targets devices for neurological conditions, an area with clinical demand — though clinical and regulatory outcomes can be uncertain.
Catalysts to watch
Regulatory approvals, trial readouts and commercial partnerships could move the story; these are binary events that carry both upside and downside.
Capital and runway
As a small‑cap firm, funding needs and potential dilution are important to monitor; limited cash reserves can affect development timelines.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
